| (Values in U.S. Thousands) | May, 2026 | Feb, 2026 | Nov, 2025 | Aug, 2025 | May, 2025 |
| Sales | 9,040 | 6,250 | 13,580 | 7,890 | 44,060 |
| Sales Growth | +44.64% | -53.98% | +72.12% | -82.09% | +138.81% |
| Net Income | -89,540 | -87,170 | -78,220 | -86,420 | -43,460 |
| Net Income Growth | -2.72% | -11.44% | +9.49% | -98.85% | +22.87% |
Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.
Fiscal Year End Date: 11/30